ATXS News and Press, Astria Therapeutics Inc. From 02/22/23

Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new STAR-0215 data in two poster...

Astria Therapeutics ( NASDAQ: ATXS ) said it started a phase 1b/2 trial of STAR-0215 as a preventative therapy for patients with hereditary angioedema (HAE). HAE is a disorder characterized by recurrent episodes (attacks) of severe swelling of the skin and mucous membranes. The co...

-- Initial Proof-of-Concept Results Anticipated in Mid-2024 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunologi...

Summary Shares of hereditary angioedema therapy concern Astria Therapeutics, Inc. have rallied on the back of some healthy patient data regarding its sole clinical candidate STAR-0215. The therapy’s defining characteristic is its long half-life, potentially permitting four-times-...

Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. The backbone of the company is Sebetralstat, which is currently being investigated in a phase 3 trial for the on-demand treatm...

Summary ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. ATXS' lead product candidate, STAR-0215, is an investigational compound aiming to treat the condi...

Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changi...

Astria Therapeutics , Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-c...

-- Shown Early Proof of Concept of STAR-0215’s Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of Up to 110 Days -- -- Plans to Initiate ALPHA-STAR Phase 1b/2 Trial in Hereditary Angioedema Patients in Q1 2023 -- -- Results to be discussed in a...